Previous 10 | Next 10 |
Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza ® (insulin human) Inhalation Powder) Time-in-range during waking hours remains a challenge despite advances in diabetes technology ...
DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing milestone as it has successfully scaled-up operations f...
DANBURY, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Burkhard Blank, MD, has joined the comp...
2023-05-10 12:02:47 ET Shares of MannKind (NASDAQ: MNKD) were up 15.6% Wednesday morning after the company released first-quarter earnings after the market closed on Tuesday. The company specializes in treating endocrine and orphan lung diseases, using its signature dry-powder f...
2023-05-10 10:47:03 ET Summary MannKind Corporation is a U.S. biopharmaceutical developer and marketer of inhaled therapeutics for endocrine and rare lung diseases in the United States. MannKind topped analysts on earnings and revenues on a strong increase in revenue thanks to rob...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that...
2023-05-09 23:30:34 ET Image source: The Motley Fool. MannKind (NASDAQ: MNKD) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: MannKind (MNKD) Q1 2023 Earnings Call Transcript
2023-05-09 21:29:07 ET MannKind Corporation (MNKD) Q1 2023 Earnings Conference Call May 9, 2023, 05:00 PM ET Company Participants Michael Castagna - CEO Steven Binder - CFO Conference Call Participants Oren Livnat - HC Wainwright Brandon Folkes - Cant...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the second table, titled "CONDENSED CONSOLIDATED BALANCE SHEETS", the right column header was in...
2023-05-09 16:01:48 ET MannKind press release ( NASDAQ: MNKD ): Q1 GAAP EPS of -$0.04 beats by $0.01 . Revenue of $40.62M (+238.8% Y/Y) beats by $3.22M . For further details see: MannKind GAAP EPS of -$0.04 beats by $0.01, revenue of $40.62M beats by $3.22M
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17%...
17-week endpoint results comparing Afrezza ® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck ...